Antibodies against Marinobacter algicola and Salmonella typhimurium Flagellins Do Not Cross-Neutralize TLR5 Activation

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Terron Exposito, Raul ^a   Dudognon, Benoit ^b   Galindo, Inmaculada ^a   Quetglas, Jose I ^c   Coll, Julio M ^a   Escribano, Jose M ^a   Gomez Casado, Eduardo ^a  

^a INIA   (Spain)

^b Alternative Gene Expression S L (ALGENEX S L)   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; EPITOPE; FLAGELLIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; TOLL LIKE RECEPTOR 5;

ACUTE KIDNEY FAILURE; ANTIBODY RESPONSE; ARTICLE; BONE MARROW TRANSPLANTATION; CONCENTRATION (PARAMETERS); CROSS NEUTRALIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL PROCEDURES; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; ISCHEMIA; MALIGNANT NEOPLASTIC DISEASE; MARINOBACTER; MARINOBACTER ALGICOLA; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SALMONELLA TYPHIMURIUM;

ADAPTIVE IMMUNITY; ANIMALS; FEMALE; FLAGELLIN; MARINOBACTER; MICE; MICE, INBRED BALB C; SALMONELLA TYPHIMURIUM; TOLL-LIKE RECEPTOR 5;

MARINOBACTER ALGICOLA; SALMONELLA TYPHIMURIUM;

EID: 84869129699     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048466     Document Type: Article

References (62)

1. Pijper A, (1948) Bacterial flagella and motility. Nature 161: 200.
2. Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, et al. (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164: 5998-6004.
3. Basset C, Holton J, O'Mahony R, Roitt I, (2003) Innate immunity and pathogen-host interaction. Vaccine 21 (Suppl 2):: S12-23.
4. Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, et al. (2005) Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A 102: 9247-9252.
5. Lien E, Golenbock DT, (2003) Adjuvants and their signaling pathways: beyond TLRs. Nat Immunol 4: 1162-1164.
6. Marciani DJ, (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8: 934-943.
7. Honko AN, Mizel SB, (2005) Effects of flagellin on innate and adaptive immunity. Immunol Res 33: 83-101.
8. Le Moigne V, Robreau G, Mahana W, (2008) Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen. Mol Immunol 45: 2499-2507.
9. Mizel SB, Bates JT, (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185: 5677-5682.
10. Skountzou I, del Pilar Martin M, Wang B, Ye L, Koutsonanos D, et al. (2010) Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28: 4103-4112.
11. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, et al. (2008) An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320: 226-230.
12. Vijay-Kumar M, Aitken JD, Sanders CJ, Frias A, Sloane VM, et al. (2008) Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 180: 8280-8285.
13. Jones RM, Sloane VM, Wu H, Luo L, Kumar A, et al. (2011) Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut 60: 648-657.
14. Gustafsson AB, Sayen MR, Williams SD, Crow MT, Gottlieb RA, (2002) TAT protein transduction into isolated perfused hearts: TAT-apoptosis repressor with caspase recruitment domain is cardioprotective. Circulation 106: 735-739.
15. Fukuzawa N, Petro M, Baldwin WM 3rd, Gudkov AV, Fairchild RL, (2011) A TLR5 Agonist Inhibits Acute Renal Ischemic Failure. J Immunol 187 (7) (): 3831-3839.
16. Hossain MS, Jaye DL, Pollack BP, Farris AB, Tselanyane ML, et al. (2011) Flagellin, a TLR5 Agonist, Reduces Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation Recipients While Enhancing Antiviral Immunity. Journal of immunology 187: 5130-5140.
17. Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, et al. (2006) Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 176: 6624-6630.
18. Rhee SH, Im E, Pothoulakis C, (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135: 518-528.
19. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, et al. (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71: 2466-2475.
20. Garaude J, Kent A, van Rooijen N, Blander JM, (2012) Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Science translational medicine 4: 120ra116.
21. Song EJ, Kang MJ, Kim YS, Kim SM, Lee SE, et al. (2011) Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med 28: 115-119.
22. Honko AN, Sriranganathan N, Lees CJ, Mizel SB, (2006) Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74: 1113-1120.
23. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, et al. (2007) A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195: 1607-1617.
24. Leng J, Stout-Delgado HW, Kavita U, Jacobs A, Tang J, et al. (2011) Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine 29 (45) (): 8147-8155.
25. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, et al. (2011) Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 6: e20928.
26. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, et al. (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152.
27. Bargieri DY, Soares IS, Costa FT, Braga CJ, Ferreira LC, et al. (2011) Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans? J Parasitol Res 2011: 965369.
28. Camacho AG, Teixeira LH, Bargieri DY, Boscardin SB, Soares Ida S, et al. (2011) TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium. Mem Inst Oswaldo Cruz 106 (Suppl 1):: 167-171.
29. McNeilly TN, Naylor SW, Mahajan A, Mitchell MC, McAteer S, et al. (2008) Escherichia coli O157:H7 colonization in cattle following systemic and mucosal immunization with purified H7 flagellin. Infect Immun 76: 2594-2602.
30. Munoz N, Van Maele L, Marques JM, Rial A, Sirard JC, et al. (2010) Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun 78: 4226-4233.
31. Newton SM, Jacob CO, Stocker BA, (1989) Immune response to cholera toxin epitope inserted in Salmonella flagellin. Science 244: 70-72.
32. Strindelius L, Filler M, Sjoholm I, (2004) Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. Vaccine 22: 3797-3808.
33. Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, et al. (2006) Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 24: 6240-6249.
34. Weimer ET, Ervin SE, Wozniak DJ, Mizel SB, (2009) Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 27: 6762-6769.
35. Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB, (2009) A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 77: 2356-2366.
36. Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, et al. (2006) A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74: 694-702.
37. Chen YS, Hsiao YS, Lin HH, Liu Y, Chen YL, (2006) CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun 74: 1699-1705.
38. Jiao XD, Hu YH, Sun L, (2010) Dissection and localization of the immunostimulating domain of Edwardsiella tarda FliC. Vaccine 28: 5635-5640.
39. Liang H, Xia L, Wu Z, Jian J, Lu Y, (2010) Expression, characterization and immunogenicity of flagellin FlaC from Vibrio alginolyticus strain HY9901. Fish Shellfish Immunol 29: 343-348.
40. Liang HY, Xia LQ, Wu ZH, Jian JC, Lu YS, (2010) Expression, purification and antibody preparation of flagellin FlaA from Vibrio alginolyticus strain HY9901. Lett Appl Microbiol 50: 181-186.
41. Wu JY, Newton S, Judd A, Stocker B, Robinson WS, (1989) Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella. Proc Natl Acad Sci U S A 86: 4726-4730.
42. Ciacci-Woolwine F, Blomfield IC, Richardson SH, Mizel SB, (1998) Salmonella flagellin induces tumor necrosis factor alpha in a human promonocytic cell line. Infect Immun 66: 1127-1134.
43. Nempont C, Cayet D, Rumbo M, Bompard C, Villeret V, et al. (2008) Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 181: 2036-2043.
44. McDermott PF, Ciacci-Woolwine F, Snipes JA, Mizel SB, (2000) High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 68: 5525-5529.
45. McNeilly TN, Mitchell MC, Nisbet AJ, McAteer S, Erridge C, et al. (2010) IgA and IgG antibody responses following systemic immunization of cattle with native H7 flagellin differ in epitope recognition and capacity to neutralise TLR5 signalling. Vaccine 28: 1412-1421.
46. Cong Y, Feng T, Fujihashi K, Schoeb TR, Elson CO, (2009) A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A 106: 19256-19261.
47. Gauthier MJ, Lafay B, Christen R, Fernandez L, Acquaviva M, et al. (1992) Marinobacter hydrocarbonoclasticus gen. nov., sp. nov., a new, extremely halotolerant, hydrocarbon-degrading marine bacterium. Int J Syst Bacteriol 42: 568-576.
48. Green DH, Bowman JP, Smith EA, Gutierrez T, Bolch CJ, (2006) Marinobacter algicola sp. nov., isolated from laboratory cultures of paralytic shellfish toxin-producing dinoflagellates. Int J Syst Evol Microbiol 56: 523-527.
49. Grimaud R (2010) Marinobacter. In: Timmis KN, editor. Handbook of Hydrocarbon and Lipid Microbiology Berlin: Springer-Verlag. pp. 1289-1296.
50. Wu CK, Gousset K, Hughes SH, (2007) Targeting to the endoplasmic reticulum improves the folding of recombinant human telomerase reverse transcriptase. Protein Expr Purif 56: 8-19.
51. Gomez-Casado E, Gomez-Sebastian S, Nunez MC, Lasa-Covarrubias R, Martinez-Pulgarin S, et al. (2011) Insect larvae biofactories as a platform for influenza vaccine production. Protein Expr Purif 79 (1) (): 35-43.
52. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
53. Alonso C, Miskin J, Hernaez B, Fernandez-Zapatero P, Soto L, et al. (2001) African swine fever virus protein p54 interacts with the microtubular motor complex through direct binding to light-chain dynein. Journal of virology 75: 9819-9827.
54. Hernaez B, Tarrago T, Giralt E, Escribano JM, Alonso C, (2010) Small peptide inhibitors disrupt a high-affinity interaction between cytoplasmic dynein and a viral cargo protein. Journal of virology 84: 10792-10801.
55. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
56. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, et al. (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4: 1247-1253.
57. Liu F, Yang J, Zhang Y, Zhou D, Chen Y, et al. (2010) Recombinant flagellins with partial deletions of the hypervariable domain lose antigenicity but not mucosal adjuvancy. Biochem Biophys Res Commun 392: 582-587.
58. Sanders CJ, Franchi L, Yarovinsky F, Uematsu S, Akira S, et al. (2009) Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur J Immunol 39: 359-371.
59. Saha S, Takeshita F, Matsuda T, Jounai N, Kobiyama K, et al. (2007) Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. J Immunol 179: 1147-1154.
60. Li Y, Liu F, Han C, Yan H, (2012) Monoclonal antibody that blocks the Toll-like receptor 5 binding region of flagellin. Hybridoma 31: 60-62.
61. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, et al. (2012) Structural basis of TLR5-flagellin recognition and signaling. Science 335: 859-864.
62. Rolli J, Rosenblatt-Velin N, Li J, Loukili N, Levrand S, et al. (2010) Bacterial flagellin triggers cardiac innate immune responses and acute contractile dysfunction. PLoS ONE 5: e12687.